TGFB1 and neoplasm: Finally, a partial reversal of tumor EMT with TGFβ-, AXL- and YAP-targeting therapies [76,171,175] may re-sensitize tumors to immunotherapies by restoring antigen expression and allowing tumor T-cell infiltration.